$64.1MSeries B, 4 September 2025
Funds a Phase 2b trial of MH002 in mild-to-moderate ulcerative colitis.
- Amount
- $64.1M
- Stage
- Series B
- Announced
- 4 September 2025
- Lead
- Biocodex
- Other investors
- ATHOS, BNP Paribas Fortis Private Equity, SFPIM, Ackermans & van Haaren, OMX, Qbic II, VIB
- Use of funds
- Funds a Phase 2b trial of MH002 in mild-to-moderate ulcerative colitis.
- Checked
- Announced by the company
- Sources
- MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeli biospace.com
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeli news.google.com
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeli news.google.com